Reporting suspected adverse reactions following vaccination against mpox (monkeypox)
16 décembre 2022
The Bavarian Nordic smallpox vaccine, which is authorised in Europe, is also effective against mpox (monkeypox). It has been available in Switzerland as a preventive measure for high-risk individuals since November 2022. Suspected adverse drug reactions should be reported to Swissmedic.
For more information, see here.